API
< Back to all clusters
[HEALTH] · India, United States · 3 sources

started · updated

GLP-1 receptor agonists show potential in diabetes and gut injury studies

A systematic review and meta-analysis published in Frontiers in Endocrinology suggests that ecnoglutide, a long-acting GLP-1 receptor agonist, may significantly improve glycemic control and reduce body weight in adults with type 2 diabetes. The analysis of three trials involving 977 participants found that ecnoglutide was associated with an average HbA1c reduction of 1.40 percentage points and an average body-weight reduction of 2.16 kilograms compared to a placebo. The study noted a dose-dependent relationship for glucose and weight improvements, though researchers cautioned that larger multicenter clinical trials are needed to confirm these findings.

In a separate study published in Cell Reports Medicine, researchers investigated the protective effects of glucagon-like peptides on the intestinal lining. Using mouse models, the study found that signaling through GLP-1 and GLP-2 receptors helped limit intestinal damage induced by activated T cells. Specifically, semaglutide and teduglutide, which activate these respective receptors, were shown to reduce gut injury. The findings suggest that gut-derived GLP hormones may play a role in protecting the intestine during acute inflammation.

Entities

Cell Reports Medicine · Frontiers in Endocrinology · ecnoglutide · semaglutide · teduglutide